These pilot results motivate multicenter longitudinal studies to further investigate blood-based biomarkers such as GFAP and NfL as a complementary tool to better understand and monitor neurological disease progression in ETPKU for the following three reasons. The gene discussed is GFAP; the disease is nervous system disorder.